Shanghai Fosun Pharmaceutical (Group) Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 21,274.61 million compared to CNY 16,877.54 million a year ago. Net income was CNY 1,553.5 million compared to CNY 2,482.37 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.74 CNY | +1.02% | +0.18% | -9.15% |
Apr. 18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
Apr. 17 | Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.15% | 7.49B | |
+25.46% | 659B | |
+26.60% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.21% | 215B | |
+8.11% | 210B | |
-6.05% | 200B | |
-8.79% | 149B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022